

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 13.11.2021

The Head- Listing Compliance
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. **Saturday, 13th day of November, 2021** (commenced at **03:00 P.M.** and concluded at **03:50 P.M.**), has inter alia approved and passed the following resolutions:

1. The **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2021. **(Copy enclosed)**
2. Took note of the **Limited Review Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and half year ended September 30, 2021. **(Copy enclosed)**
3. Took note of the **Cash Flow Statement** as per Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for quarter and half year ended September 30, 2021. **(Copy enclosed)**
4. Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended September 30, 2021.
5. Took note of Closure of Trading Window for Designated Persons as required under SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 for the quarter ended September 30, 2021.
6. Took note of Certificate of Non Applicability of Compliance with Report on Corporate Governance as required under Regulation 27(2) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter ended September 30, 2021.
7. Took note of The Reconciliation of Share Capital Audit Report Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2021.

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

8. Took note of Shareholding pattern pursuant to Regulation 31 of the (Listing Obligations and Disclosure Requirements) Regulation 2015 for the quarter ended September 30, 2021.
9. Took note of Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2021.

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

Ajai Goyal
Whole Time Director
DIN: 02636418

Place: Noida



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470 (Basement), Hudson Line, GTB Nagar, Delhi-110009


Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER, 2021.

To
The Board of Directors
Raymed Labs Limited
103 Emperor 1, Supertech Emerald Court,
Sector 93A, Noida - 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the period ended on 30th September, 2021, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of



Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay. Mehra & Co.
Chartered Accountants
ERN-050004C



Deepak Suneja
Deepak Suneja
(Partner)

(Membership NO- 501957)

Date: November 13, 2021

Place: Noida

UDIN:- 21501957AAAANX9835

| | | | | | | |
|---|--------------|--------------|--------------|--------------|--------------|--------------|
| IX. Profit/(Loss) for the period from continuing operations (VII-VIII) | -1.27 | -0.91 | -0.18 | -2.18 | -0.73 | -6.88 |
| X. Profit/(Loss) from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | | 0.00 |
| XI. Tax expense of discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII. Profit/(Loss) for the period (IX+XII) | -1.27 | -0.91 | -0.18 | -2.18 | -0.73 | -6.88 |
| XIV. Other Comprehensive Income | 0.00 | 0.00 | 0.00 | 0.00 | | 0.00 |
| (A) (i) Items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (B) (i) Items that will be classified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (ii) Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period) | -1.27 | -0.91 | -0.18 | -2.18 | -0.73 | -6.88 |
| XVI. Paid up Equity Share Capital (Face Value of Rs. 10/- Each) | 427.35 | 427.35 | 427.35 | 427.35 | 427.35 | 427.35 |
| XVII. Other Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -632.64 |
| XIX. Earnings per equity share (for continuing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

| | | | | | | |
|--|---------|---------|---------|---------|---------|---------|
| operation): | | | | | | |
| (1) Basic | -0.0297 | -0.0214 | -0.0041 | -0.0511 | -0.0171 | -0.1611 |
| (2) Diluted | -0.0297 | -0.0214 | -0.0041 | -0.0511 | -0.0171 | -0.1611 |
| XX. Earnings per equity share (for discontinued operation): | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| (1) Basic | 0.000 | 0.000 | 0.000 | 0.00 | 0.00 | 0.00 |
| (2) Diluted | 0.000 | 0.000 | 0.000 | 0.00 | 0.00 | 0.00 |
| XXI. Earnings per equity share (for discontinued & continuing operations) | | | | | | |
| (1) Basic | -0.0297 | -0.0214 | -0.0041 | -0.0511 | -0.0171 | -0.1611 |
| (2) Diluted | -0.0297 | -0.0214 | -0.0041 | -0.0511 | -0.0171 | -0.1611 |

Notes:

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13th November 2021. The Statutory Auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.

(2) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.

(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

**For on behalf of
Raymed Labs Limited**

**Ajai Goyal
Director
DIN : 02636418
Date: 13.11.2021
Place : Noida**

Statement of Audited Standalone/Consolidated Assets and Liabilities

Amount in Lakhs.

| Particulars | As at Current Half Year Ended | As at Previous Year Ended |
|--|----------------------------------|------------------------------|
| | 30.09.2021 | 31.03.2021 |
| | (Unaudited) | (Audited) |
| ASSETS | | |
| Non current assets | | |
| (a) Property, Plant and Equipment | 15.83 | 16.09 |
| (b) Capital Work in Progress | 0.00 | 0.00 |
| (c) Investment Property | 0.00 | 0.00 |
| (d) Goodwill | 0.00 | 0.00 |
| (e) Other Intangible Assets | 0.03 | 0.03 |
| (f) Intangible assets under development | 0.00 | 0.00 |
| (g) Biological Assets other than bearer plants | 0.00 | 0.00 |
| (h) Financials Assets- | | |
| (i) Investments | 0.00 | 0.00 |
| (ii) Trade Receivables | 0.00 | 0.00 |
| (iii) Loans | 0.00 | 0.00 |
| (iv) Other(to be specified) | 0.00 | 0.00 |
| (i) Deferred tax assets (net) | 0.00 | 0.00 |
| (j) Other non-current assets | 0.00 | 0.00 |
| Current Assets | | |
| (a) Inventories | 0.00 | 0.00 |
| (b) Financials Assets | | |
| (i) Investments | 0.00 | 0.00 |
| (ii) Trade receivables | 2.49 | 2.49 |
| (iii) Cash and cash equivalents | 0.05 | 0.15 |
| (iv) Bank Balance other than (iii) above | 0.03 | 0.03 |
| (v) Loans | 6.10 | 6.10 |
| (vi) Others (to be specified) | 0.00 | 0.00 |
| (c) Current tax Assets | 0.00 | 0.00 |
| (d) Other current Assets | 0.28 | 0.28 |
| TOTAL ASSETS | 24.81 | 25.16 |

| EQUITY AND LIABILITES | | |
|--|--------------|--------------|
| Equity- | | |
| (a) Equity Share Capital | 427.35 | 427.35 |
| (b) Other Equity | -634.82 | -632.64 |
| Liabilities | | |
| Non -Current liabilities | | |
| (a) Financials Liabilities | | |
| (i) Borrowings | 0.00 | 0.00 |
| (ii) Trade Payable | 0.00 | 0.00 |
| (iii) Other Financial liabilities (other than specified in item (b) to be specified) | 0.00 | 0.00 |
| (b) Provisions | 0.00 | 0.00 |
| (c) Deffered Tax Liabilites (net) | 0.00 | 0.00 |
| (d) Other Non-Current Liabilities | 0.00 | 0.00 |
| Current Liabilities | | |
| (a) Financials Liabilities | | |
| (i) Borrowings | 217.55 | 216.33 |
| (ii) Trade Payables | 6.21 | 5.60 |
| (iii) Other Financial liabilities (other than specified in item (c) to be specified) | 5.00 | 5.00 |
| (b) Other current liabilities | 0.28 | 0.28 |
| (c) provisions | 3.24 | 3.24 |
| (d) Current Tax Liabltries | 0.00 | 0.00 |
| | | |
| TOTAL EQUITY AND LIABILITES | 24.81 | 25.16 |

For on behalf of Raymed Labs Limited

Ajai Goyal
Director
DIN : 02636418

Date: 13.11.2021
Place : Noida

Raymed Labs Limited
Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,
Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,
Tel: 0120-2426900, 9412700300

UNAUDITED STANDALONE &/OR CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2021

| <i>Particulars</i> | Six Months ended September 30, 2021 (01.04.2021 to 30.09.2021) (Unaudited) |
|--|---|
| Cash flow from Operating Activities | |
| Profit Before Tax | -2.18 |
| Adjustments for | |
| Adjustments for finance costs | |
| Adjustments for decrease (increase) in inventories | |
| Adjustments for decrease (increase) in trade receivables, current | |
| Adjustments for decrease (increase) in trade receivables, non-current | |
| Adjustments for decrease (increase) in other current assets | |
| Adjustments for other financial assets, non-current | |
| Adjustments for other financial assets, current | |
| Adjustments for other bank balances | |
| Adjustments for increase (decrease) in trade payables, current | |
| Adjustments for increase (decrease) in trade payables, non-current | |
| Adjustments for increase (decrease) in other current liabilities | 0.61 |
| Adjustments for increase (decrease) in other non-current liabilities | |
| Adjustments for depreciation and amortisation expense | 0.26 |
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | |
| Adjustments for provisions, current | |
| Adjustments for provisions, non-current | |
| Adjustments for other financial liabilities, current | 1.22 |
| Adjustments for other financial liabilities, non-current | |
| Adjustments for unrealised foreign exchange losses gains | |
| Adjustments for dividend income | |
| Adjustments for interest income | |
| Adjustments for share-based payments | |
| Adjustments for fair value losses (gains) | |
| Adjustments for undistributed profits of associates | |
| Other adjustments for which cash effects are investing or financing cash flow | |
| Other adjustments to reconcile profit (loss) | |
| Other adjustments for non-cash items | |

| | |
|---|-------|
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | |
| Total adjustments for reconcile profit (loss) | 2.09 |
| Net cash flows from (used in) operations | -0.10 |
| Dividends received | |
| Interest paid | |
| Interest received | |
| Income taxes paid (refund) | |
| Other inflows (outflows) of cash | |
| Net cash flows from (used in) operating activities | -0.10 |
| Cash flows from used in investing activities | |
| Cash flows from losing control of subsidiaries or other businesses | |
| Cash flows used in obtaining control of subsidiaries or other businesses | |
| Other cash receipts from sales of equity or debt instruments of other entities | |
| Other cash payments to acquire equity or debt instruments of other entities | |
| Other cash receipts from sales of interests in joint ventures | |
| Other cash payments to acquire interests in joint ventures | |
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | |
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | |
| Proceeds from sales of property, plant and equipment | |
| Purchase of property, plant and equipment | |
| Proceeds from sales of investment property | |
| Purchase of investment property | |
| Proceeds from sales of intangible assets | |
| Purchase of intangible assets | |
| Proceeds from sales of intangible assets under development | |
| Purchase of intangible assets under development | |
| Proceeds from sales of goodwill | |
| Purchase of goodwill | |
| Proceeds from biological assets other than bearer plants | |
| Purchase of biological assets other than bearer plants | |
| Proceeds from government grants | |
| Proceeds from sales of other long-term assets | |
| Cash receipts from repayment of advances and loans made to other parties | |
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | |
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | |
| Dividends received | |
| Interest received | |
| Income taxes paid (refund) | |

| | |
|--|-------|
| Other inflows (outflows) of cash | |
| Net cash flows from (used in) investing activities | |
| Cash flows from used in financing activities | |
| Proceeds from changes in ownership interests in subsidiaries | |
| Payments from changes in ownership interests in subsidiaries | |
| Proceeds from issuing shares | |
| Proceeds from issuing other equity instruments | |
| Payments to acquire or redeem entity's shares | |
| Payments of other equity instruments | |
| Proceeds from exercise of stock options | |
| Proceeds from issuing debentures notes bonds etc | |
| Proceeds from borrowings | |
| Repayments of borrowings | |
| Payments of finance lease liabilities | |
| Payments of lease liabilities | |
| Dividends paid | |
| Interest Paid | |
| Income taxes paid (refund) | |
| Other inflows (outflows) of cash | |
| Net cash flows from (used in) financing activities | |
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -0.10 |
| Effect of exchange rate changes on cash and cash equivalents | 0.00 |
| Effect of exchange rate changes on cash and cash equivalents | 0.00 |
| Net increase (decrease) in cash and cash equivalents | -0.10 |
| Cash and cash equivalents cash flow statement at beginning of period | 0.15 |
| Cash and cash equivalents cash flow statement at end of period | 0.05 |

Notes : The above results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 13.11.2021. The Statutory auditors have conducted a limited review of the above unaudited financial results and have expressed an unmodified report on the same.

For or on behalf of Raymed Labs Limited

Ajai Goyal
Director
DIN: 02636418

Date: 13.11.2021
Place: Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 13.11.2021

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Scrip Code: 531207

Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter and half year ended September 30, 2021

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

Kindly take the same in your records.

Thanking You,

Yours Sincerely,

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

Place: Noida